Synaptogenix welcomes lecanemab phase 3 trial results

Synaptogenix expecting data from its phase 2 clinical trial of bryostatin-1 for advanced alzheimer's disease in fourth quarter 2022 new york , sept. 28, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today commented on the positive phase 3 trial results for lecanemab announced last night by eisai and biogen.
SNPX Ratings Summary
SNPX Quant Ranking